Autoimmune and non-immune apoptosis, or programmed death, of pancreatic beta cells results in type 1 diabetes mellitus. Normal beta-cell survival entails complex regulation of multiple hormones and fundamental growth factors, including the insulin-like growth factors (IGFs). IGF binding proteins (IGFBPs) sequester IGFs in body tissues and blood, thereby controlling bioavailability of lGFs for their receptors. IGFBPs dramatically impact cell proliferation, apoptosis, and physiology via both IGF-dependent and IGF-independent mechanisms. Work in several cell culture and animal models has confirmed that the pancreatic islets provide a fertile environment for actions of multiple IGF axis components. Manipulating this axis to understand and ultimately control the pathways regulating beta cell survival is key to multiple strategies for restoring insulin secretion. Recently, it has been discovered that IGFBP-3, the major IGFBP in serum, induces apoptosis in diverse cancer cell types via direct, functional interactions with the nuclear retinoic X receptor-alpha (RXR-alpha), the first nuclear receptor identified for any IGFBP. Several cytokines have been implicated in beta cell apoptosis, including tumor necrosis factor-alpha (TNF-alpha). We have recently discovered that TNF-alpha-induced beta cell apoptosis requires de novo transcription of IGFBP-3. Moreover, we have discovered that TNF-alpha induces IGFBP-3 production and increases the nuclear content of IGFBP-3 in beta cells. We have developed two new mouse models; a transgenic designed to specifically over-express IGFBP-3 in the islets, and mice which lack IGFBP-3, but possesses alleles associated with type 1 diabetes (namely the iddm alleles of the non-obese diabetic mouse. These latter NOD/BP3-/-mice appear to manifest improved glucose tolerance in vivo, suggesting that loss of IGFBP-3 may protect from beta-cell apoptosis. These data are compelling to pursue because they present novel targets for controlling beta cell survival and for improving beta cell function. Our central hypothesis is that IGF axis components, IGFBP-3 and IGF-I in particular are critical regulators of beta-cell survival and insulin secretion and therefore play central roles in the pathogenesis of type 1 and type 2 diabetes. We propose to: 1) determine the relationship between IGFBP-3 and RXR-alpha in beta-cell apoptosis and dysfunction; 2) develop novel transgenic rodent models overexpressing select native and mutant IGF axis components in an islet-specific manner; 3) determine the requirement of IGFBP-3 for beta-cell apoptosis in vivo, and 4) assess whether overexpression of IGFBP-3 antagonists in the islets protects NOD mice from developing diabetes. These studies promise to improve our understanding of the pathogenesis of diabetes and may open novel therapeutic approaches to prevention and treatment of diabetes. The UCLA Department of Pediatrics has dedicated extensive resources to support the research activities and career development of its junior faculty. This Department has established mentoring programs to transition junior faculty from dependence to independence, and, ultimately, interdependence as pediatrician scientists. The resources of the candidate's department will leverage the support from this grant on a """"""""dollar-for-dollar"""""""" basis, and thereby propel not only the proposed scientific work but also the emergence of the candidate as an independent pediatrician-scientist during the time period of this award.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK002876-02
Application #
6524072
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2001-09-01
Project End
2002-08-31
Budget Start
2002-08-01
Budget End
2002-08-31
Support Year
2
Fiscal Year
2002
Total Cost
$1
Indirect Cost
Name
University of California Los Angeles
Department
Pediatrics
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Barrett, Jeffrey C; Clayton, David G; Concannon, Patrick et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703-7
Schlabritz-Loutsevitch, Natalia E; Lopez-Alvarenga, Juan C; Comuzzie, Anthony G et al. (2009) The prolonged effect of repeated maternal glucocorticoid exposure on the maternal and fetal leptin/insulin-like growth factor axis in Papio species. Reprod Sci 16:308-19
Melamed, Esther; Wyatt, Lacey E; Padilla, Tony et al. (2008) Patient-based cultural competency curriculum for pre-health professionals. Fam Med 40:726-33
Li, C; Levitz, M; Hubbard, G B et al. (2007) The IGF axis in baboon pregnancy: placental and systemic responses to feeding 70% global ad libitum diet. Placenta 28:1200-10
Vasylyeva, Tetyana L; Ferry Jr, Robert J (2007) Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract 76:177-86
Chen, Xiaoyan; Ferry Jr, Robert J (2006) Novel actions of IGFBP-3 on intracellular signaling pathways of insulin-secreting cells. Growth Horm IGF Res 16:41-8
Vasylyeva, Tetyana L; Chen, Xiaoyan; Ferry Jr, Robert J (2005) Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res 15:207-14
Ferry Jr, Robert J; Cohen, Pinchas; Levitt Katz, Lorraine E (2005) Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children. Horm Res 63:220-7
Shim, Melanie L; Levitt Katz, Lorraine E; Davis, Jason et al. (2004) Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. Growth Horm IGF Res 14:216-25
Granata, R; De Petrini, M; Trovato, L et al. (2003) Insulin-like growth factor binding protein-3 mediates serum starvation- and doxorubicin-induced apoptosis in H9c2 cardiac cells. J Endocrinol Invest 26:1231-41

Showing the most recent 10 out of 11 publications